Barclays raised the firm’s price target on Johnson & Johnson to $197 from $176 and keeps an Equal Weight rating on the shares. The firm updated the company’s estimates.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- Midday Fly By: Nvidia invests in Synopsys, U.S. strikes pharma deal with UK
- Trump Trade: U.S. confirms agreement with U.K. on pharmaceutical pricing
- Is AstraZeneca’s Stock (AZN) a Good Investment Right Now?
- US government confirms agreement in principle with UK on pharmaceutical pricing
- US, UK expected to agree on zero-tariffs pharmaecuticals deal, UK Times says